New AstraZeneca Drug For HER2-Low Breast Cancer Aces Phase III Trial
Not all cancer cases are created equal. As the medical community hones in on better, less invasive cancer treatments, differentiating between different types of cases is key. Breast cancer is an example of a cancer that manifests in several different ways, requiring different treatment regimens. The presence of human epidermal growth factor receptor 2, or HER2, is one of those key differentiators. Now, drug manufacturer AstraZeneca has aced a Phase III trial for its new drug, Enhertu, which seeks to treat breast cancer cases classified as “HER2-low.” Read on to find out more about this exciting new drug prospect.
To learn more about QPS, visit their Clinical Leader page.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.